ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

2024 Updates in Ovarian Cancer

Total Health

T. Tillmanns

ASCO® 2024 Summary: "Timing of Debulking Surgery in Advanced Endomet…

2024 ASCO® Annual Meeting Insights Hub

A. Karam

Defining Platinum Resistance in Ovarian Cancer

Michael Birrer

Management of Recurrent Ovarian Clear Cell Carcinoma

David Tan

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Insights from 2023 ESMO Annual Meeting

M. Raza Mirza

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+ Sol…

UCSF School of Medicine

H. Kang

The Role of Surgery in Stage IV Ovarian Cancer

Insights from 2024 ESMO Gynaecological Cancers Congress

C. Fotopoulou

Antibody Drug Conjugates in Gynecologic Oncology: From Bench to Beds…

UCLA Health

G. Konecny

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

Precision Oncology in the Management of Ovarian Cancer

Miami Cancer Institute Precision Oncology Symposium

D. Dizon

Overview of Ovarian Cancer Updates

Masonic Cancer Center, University of Minnesota

J. Mattson

Year in Review: Ovarian Cancer

Fengting Yan

ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian C…

ecancer

A. González-Martín

ESMO 2024 Insights: Mirvetuximab Soravtansine-gynx (MIRV) in Platinu…

2024 ESMO Annual Meeting Insights Hub

A. Secord